Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections.
With resistance of S. aureus, the most prevalent identified pathogen in skin and soft tissue infections, on the rise, the need for safe, effective, and well-tolerated antibiotics is crucial. Ceftobiprole medocaril (BAL-5788), ceftobiprole's parenteral prodrug, is a bactericidal cephalosporin with broad Gram-positive and Gram-negative activity that has shown to be well-tolerated and noninferior to vancomycin and vancomycin plus ceftazidime in the treatment of MRSA complicated skin and skin structure infections (cSSSIs) in clinical trials. Areas Covered: This article overviews ceftobiprole medocaril's use for cSSSI, with specific focus on clinical efficacy and safety data in addition to summary information on its basic chemistry, microbiological profile, and pharmacokinetic/pharmacodynamic relationships supporting its use in cSSSIs. Information sources include peer-reviewed scientific literature, conference proceedings, publically available regulatory reports, as well as information from the drug sponsor's website. Expert Commentary: With increasing antibiotic resistance, safe, effective antibiotics agents are a welcome sight. There has been clinical evidence in support of using ceftobiprole for treatment of Gram-positive and -negative infections, including MRSA and susceptible P. aeruginosa. This broad antimicrobial activity might allow ceftobiprole to be an alternative to dual therapy combinations when potential drug toxicities, drug-drug or drug-disease interactions are concerns for other agents.
a University of Florida College of Pharmacy , Florida , United States.
Amelia
A
Deitchman
a University of Florida College of Pharmacy , Florida , United States.
Daniel
D
de Jong
b Merck & Co., Inc , United States.
April
A
Barbour
a University of Florida College of Pharmacy , Florida , United States.
Hartmut
H
Derendorf
Cephalosporins; antibiotics; antiinfectives